pixlbio (formerly Phenaros) ^Company

pixlbio is a TechBio company combining human iPSC-derived cell models with AI-powered phenomics for drug discovery and safety research. Formed in 2025 from the merger of DefiniGEN — a pioneer in iPSC-derived hepatocyte technology founded at the University of Cambridge — and Phenaros, a Swedish AI phenomics company. pixlbio supplies iPSC-derived hepatocytes (pixHep), stellate cells (pixStellate), intestinal organoids (pixIO), and disease models for MASLD, A1ATD, PFIC2, and urea cycle disorders, alongside Cell Painting phenomics and end-to-end drug discovery services. Trusted by numerous global pharmaceutical companies including AstraZeneca and Sanofi.